US EditionEvoque tricuspid valve replacement system gains Health Canada approval - Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Evoque Tricuspid Valve Replacement System From Edwards Approved in Canada - Cardiac Interventions Today
June 24, 2025—Edwards Lifesciences Corporation announced that the company’s Evoque tricuspid valve replacement system has received Health Canada approval for the treatment of tricuspid regurgitation (TR). According to the company, the Evoque system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT) and for whom tricuspid valve replacement is deemed appropriate by a heart…
Evoque tricuspid valve replacement system gains Health Canada approval - Cardiovascular News
Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system. Edwards Lifesciences has announced that the company’s Evoque tricuspid valve replacement system has received Health Canada’s approval for the treatment of tricuspid regurgitation (TR). The Evoque system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
